AI Drug Discovery Has a $1.46 Billion Question AstraZeneca’s insitro deal and Iambic’s IPO reveal the next test for AI: deciding which drug programs deserve the cost of human trials.

🤰🔬 What if software could help transform prenatal screening into smarter, more informed decisions? Prenatal Diagnostic Software is reshaping how healthcare professionals analyze data, support clinical decisions, and navigate pregnancy care. 🧬📊 As technology advances, what’s next for this evolving market? 📈 Explore the insights from Roots Analysis’ Prenatal Diagnostics Report. #PrenatalDiagnostics #HealthTech #MedTech #DigitalHealth #MarketIntelligence

Could radiopharmaceuticals reshape precision oncology? The global market is projected to grow from $13.1B in 2026 to $38.6B by 2040, at an 8.0% CAGR. The opportunity goes beyond therapeutics—into theranostics, partnerships & isotope supply. #Radiopharmaceuticals #Oncology

When reading an industry report, what do you check first?

The next energy revolution could be hydrogen. The global green hydrogen market is projected to grow from $1.5B (2024) to $125.3B (2035) at a 49.5% CAGR. What's driving the shift? Clean energy, industrial decarbonization and sustainable fuels. 🔗 rootsanalysis.com/green-hydr… #GreenHydrogen #CleanEnergy

What if your next ride arrived from the sky? Flying cars are moving beyond science fiction, and the market opportunity is taking shape. According to Roots Analysis, the Urban Air Mobility Market could reach $206.79B by 2040, growing at a 27.85% CAGR. Would you trust a flying taxi for your daily commute? #RootsAnalysis #FlyingCars #FutureOfMobility

Finally, we are heading to the future where there actually are FLYING CARS!! #Flying #vehicles market is going to be a next big thing @Tesla #tesla #innovation #future

What Will Define the Next Generation of Cancer Therapies? Oncology innovation is accelerating. Which approach has the greatest potential to transform cancer treatment over the next decade?

$1.2B potential deal value. Is obesity drug development entering a new era? Zealand Pharma × Generate Biomedicines are betting on AI-engineered, multispecific protein therapies. The bigger question: Can AI-driven discovery translate into better treatments? #Biotech #DrugDiscovery

💉 Injectables hold 93% of GLP-1 market revenue. 💊 But oral therapies are expected to grow faster. With the market projected to hit $180B by 2035, could a pill challenge the pen? 📊 Roots Analysis: rootsanalysis.com/reports/gl… #GLP1 #Biotech

3 FDA green lights. 3 markets on the move. Roche's Tecentriq. Pfizer's TUKYSA. Teva's WELTRUZA. Beyond the approvals: shifting treatment strategies and new competitive opportunities. Introducing The Roots Intelligence Brief — every Tuesday. #Pharma #Biotech

🧬 $43.56B vs. $16.81B. Two oncology technologies. Two very different approaches. 💉 ADCs: Precision drug delivery. 🔬 Bispecifics: Dual-target engagement. Who shapes the next decade of cancer treatment? Swipe to compare 👉 #ADCs #Oncology #Biotech

What if AI doesn't just help scientists discover drugs—but starts deciding what to discover next? From AI copilots to autonomous research, pharma R&D could be entering a new era. 📈 $4.7B → $39.8B by 2035. The broader generative AI healthcare market is accelerating. But can AI-led discovery earn scientists' trust? Explore: rootsanalysis.com/reports/ge… #AIinPharma #DrugDiscovery #GenerativeAI #RootsAnalysis

The pharma CMO market is evolving fast. 🚀 What’s driving the next wave of growth, and where are the opportunities? Explore the insights. 💊📊 #PharmaCMO #Pharmaceuticals #MarketInsights #RootsAnalysis

The syringe is becoming part of the therapy. Asia-Pacific’s prefilled syringes market is projected to grow from USD 858M in 2026 to USD 1.6B by 2035 — driven by biologics, self-administration and ready-to-use delivery. 🔗 rootsanalysis.com/reports/as… #DrugDelivery #Biologics #PrefilledSyringes